Presentation of results for first quarter 2013
DiaGenic will present results for the first quarter 2013 on Wednesday 15 May 2013. Interim report and presentation slides will be posted on www.newsweb.no and on DiaGenic’s web page: www.diagenic.com on 15 May at approximately 08:00 CET.
A conference call for a presentation of the results is scheduled the same day at 12:00 CET. Please use the dial-in details listed below, corresponding to your location, to participate in the conference call. The conference ID is: 6873001
Participant Access - Dial in 5-10 minutes prior to the start of the call using one of the numbers below
| Confirmation Code: | 6873001 |
| Participants, Local - Oslo, Norway: | +472350 0486 | |
| Participants, Local - Stockholm, Sweden: | +46(0)8 5876 9446 | |
| Participants, Local - Copenhagen, Denmark: | +4538 32 28 69 | |
| Participants, Local - New York, United States of America: | +1718 354 1158 | |
| Participants, Local - London, United Kingdom: | +44(0)20 3427 1919 |
Please use the Direct Access link below to follow the presentation slides:
| Adobe Connect Web Meeting: |
| To be entered directly into your Adobe Connect web meeting click on the Direct Access Link: http://webmeeting.adobeconnect.com/e6873001 Need Help? Contact Customer Support: Phone: +353 (0) 23 88 32131 E-Mail: euvisioncast@premiereglobal.ie |
Contact:
Paul de Potocki, Chief Executive Officer
Telephone: 47 2324 8950
e-mail: paul.depotocki@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com